Stanley Druckenmiller's BEAM Position Overview
Stanley Druckenmiller (via Duquesne Family Office LLC) currently holds 153,600 shares of Beam Therapeutics Inc. (BEAM) worth $5.27 M, representing 0.10% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Stanley Druckenmiller has initiated a new position in BEAM, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Stanley Druckenmiller's Beam Therapeutics (BEAM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Beam Therapeutics (BEAM) Trades by Stanley Druckenmiller
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +153,600 | New Buy | 153,600 | $34.32 |
Stanley Druckenmiller's Beam Therapeutics Investment FAQs
Stanley Druckenmiller first purchased Beam Therapeutics Inc. (BEAM) in Q2 2026, acquiring 153,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Stanley Druckenmiller has held Beam Therapeutics Inc. (BEAM) for 1 quarters since Q2 2026.
Stanley Druckenmiller's largest addition to Beam Therapeutics Inc. (BEAM) was in Q2 2026, adding 153,600 shares worth $5.27 M.
According to the latest 13F filing for Q2 2026, Stanley Druckenmiller's firm, Duquesne Family Office LLC, owns 153,600 shares of Beam Therapeutics Inc. (BEAM), valued at approximately $5.27 M.
As of the Q2 2026 filing, Beam Therapeutics Inc. (BEAM) represents approximately 0.10% of Stanley Druckenmiller's publicly disclosed stock portfolio, making it one of their key holdings.
Stanley Druckenmiller's peak holding in Beam Therapeutics Inc. (BEAM) was 153,600 shares, as reported at the end of Q2 2026.